The assessors will score all of your questions except question 1 which is not scored.
Your answer to each question can be up to 400 words long. Do not include any URLs in your answers unless we have explicitly requested a link to a video.
Question 1. Themes (not scored)
Select one main disease from the specific disease list in the ‘Scope’ section of this competition.
Vaccine candidates or technologies must target Disease X, or pathogens from one of the following viral or bacterial families identified by the UK Vaccine Network:
Priority families : Exemplar pathogens
- Arenaviridae: Lassa fever virus
- Coronaviridae: Middle East respiratory syndrome (MERS)
- Filoviridae: Marburg virus, Sudan ebolavirus
- Flaviridae: Zika virus
- Hantaviridae: Hantaan virus
- Nairoviridae: Crimean Congo Hemorrhagic Fever (CCHF) virus
- Paramyxoviridae: Nipah virus
- Phenuiviridae: Rift Valley Fever (RVF) virus; Dabie bandavirus (formerly severe fever with thombocytopenia syndrome virus)
- Picornaviridae: Enterovirus 68
- Togaviridae: Chikungunya virus
- Coxiellaceae: Q fever (Coxiella burnetii)
- Yersiniaceae: Plague (Yersinia pestis)
Question 2. Proposed idea or technology
How does the project meet the challenge described in the competition scope?
Provide a description of your proposed idea or technology.
Include a description of the current state of development.
You can submit a single appendix as a PDF containing images and diagrams to support your answer. It can be no larger than 10MB and up to 2 A4 pages long. The font must be legible at 100% zoom.
This question will be scored against this assessment criterion: ‘Does the proposal describe a distinct package of work that will improve the readiness of the vaccine candidate or technology platform for clinical development or regulatory submission?’
Question 3. Technical project summary
What are the main technical challenges you are addressing?
- how you will improve the readiness of the vaccine candidate, platform or technology for clinical development or regulatory submission
- evidence for the scientific and commercial merit of the project based on previous research and development
- the main technical deliverables
- what will be achieved on completion of the distinct work package and how it will increase the readiness of the vaccine candidate, platform or technology for future clinical development
This question will be scored against this assessment criterion: ‘How valid is the technical approach?’.
Question 4. Intellectual property and freedom to operate
Do you have freedom to operate?
You must explain how you would handle any intellectual property (IP) issues which might arise during the project.
Include details of how you will maintain freedom to operate and fulfil the IP requirements detailed in the contract if you are working with subcontractors.
You must include details of:
- any existing intellectual property (IP)
- its significance to your freedom to operate
- novel concepts you develop or employ
- new approaches or technologies you use
- new tools or technologies
This question will be scored against these assessment criteria: ‘Are there any constraints due to existing intellectual property and have these been mitigated?’
Question 5. Project plan and methodology
Describe your project plan and identify the main milestones.
The emphasis throughout should be on practicality. We are seeking evidence that your project will move the vaccine candidate or technology platform along the development pathway, enhancing its readiness for future clinical development and putting it in a stronger place to obtain future funds.
- describe resources that will be needed to deliver the project
- describe what the main success criteria will be
- identify the project management processes that will ensure you achieve the milestones
- describe the main technical, commercial and environmental risks and what you will do to mitigate them
- set a milestone to provide a clear business case and technical plan by month 12 of your project
Please note: Applications developing standalone assays that are unrelated to specific vaccine development projects are not required to complete a business case and technical plan.
You must upload a project plan or Gantt chart as an appendix in PDF format no larger than 10MB and up to 2 A4 pages. The font must be legible at 100% zoom.
Your milestones must:
- be clear
- be defined using SMART (specific, measurable, achievable, realistic and time-bound) criteria
- be associated with the appropriate deliverables and payments
- indicate your payment schedule by month
This question will be assessed against these assessment criteria:
- does the proposal show a clear and achievable plan for completing a distinct work package that will advance the vaccine candidate, platform or technologies along the developmental pathway and help the readiness for future clinical development and funding opportunities
- is there a clear management plan and distinct project management role
- what are the main technical, commercial, and environmental risks to the project’s success
- how will these be effectively managed
- are the milestones, success criteria and evaluation procedures appropriate
Please note: information from the finances section will be used to support the assessment of this question. Proposed milestones and associated payments stated in this section must match those entered in the finance summary on your application.
Question 6. Technical team and expertise
Who is in the technical team? What expertise do they offer?
Provide a brief description of your technical team, including any subcontractors.
- how each organisation has the skills, capabilities, and experience to deliver the intended benefits
- how much of their time will be spent on the project
- the project management role
This question will be scored against this assessment criterion: Does the applicant have the skills, capabilities and experience to deliver the intended benefits?
Question 7. Costs and value for money
How much will the project cost for stage 1? How does it represent value for money for the team and the taxpayer?
- the total costs, inclusive of VAT if applicable, you are requesting in terms of the project goals
- how this project represents value for money for you and the taxpayer
- your expected overall costs for stage 2
Proposed costs stated in this section for stage 1 must match those entered in the finance summary and be appropriately justified.
All costs quoted must reflect actual costs at a ‘fair market value’ and not include profit.
You can submit a single appendix as a spreadsheet in PDF format, no larger than 10MB and up to 2 A4 pages long to support your answer. The font must be legible at 100% zoom.
Progression to stage 2 depends on your success in stage 1.
Please note: all payments are made quarterly in arrears on submission of an invoice. The invoice must be submitted within 30 days of the end of each monitoring period for all completed milestones.
Full Economic Cost (FEC) calculations are not relevant for SBRI competitions. SBRI is a competitive process and applications will come from a variety of organisations. Whatever calculation you use to arrive at your total eligible project costs your application will be assessed against applications from other organisations. Bear this in mind when calculating your total eligible project costs. You can include overheads but remember that this is a competitive process.
The assessors are required to judge the application finances in terms of value for money. They will score your finances against this assessment criterion: ‘Are the budget and costs realistic, justified and appropriate for the aims and methods?
Please note information from the finances section will be used to support the assessment of this question. Proposed costs stated in this section must match those entered in the finance summary on your application.
Question 8. ODA compliance
This competition is funded from UK Official Development Assistance (ODA). In order to be eligible for ODA funding, the primary purpose of a project must be to benefit the economic development or welfare of one or more countries on the OECD Development Assistance Committee (DAC) list. Projects may have secondary benefits beyond ODA eligible countries.
Explain why the project is eligible for ODA funding, including the merits of the technical approach for use in lower resource settings.
This question will be scored against these assessment criteria: ‘How significant is the potential benefit to populations in ODA eligible countries? Are the vaccine candidates or technology platforms appropriate for use in lower resource settings?
Question 9. Pathway to impact
Describe, with appropriate supporting evidence, the potential pathway to positive impact in ODA eligible countries after the lifespan of the award?
This question will be scored against the assessment criterion: ‘Has the project appropriately considered pathways to access the proposed vaccine candidate, platform or technologies for target populations?’